Science-based sperm technologies for better outcomes.
Advancing assisted reproduction by addressing the biological needs of sperm, mimicking natural capacitation to improve fertilization and embryo quality.
Our development is supported by collaborations with
leading clinical, scientific and industry partners.
THE SCIENCE BEHIND BETTER IVF OUTCOMES
Built on Sperm Biology
Fecundis is a biotechnology company developing sperm-centered technologies for assisted reproduction.
Decades of research in sperm capacitation are translated into practical, clinically supported tools that help IVF laboratories improve sperm function and support embryo development and ART performance.
The Missing Step in IVF
Successful fertilization depends on sperm capacitation — a biochemical transformation that naturally occurs in the female reproductive tract before sperm interact with the egg.
Where Standard Preparation Methods Fall Short
Most sperm preparation methods focus on washing and selecting motile sperm, but they do not fully reproduce the physiological signals required for optimal sperm function.
The Fecundis Approach
Fecundis technologies recreate key biochemical signals involved in physiological capacitation, helping IVF laboratories work with sperm cells in a more functionally relevant state.
Supported by published clinical evidence, this approach helps improve sperm performance and contributes to better IVF outcomes.
OUR LEAD PRODUCT
HyperSperm
HyperSperm is a sequential-step kit designed to recreate, in vitro, key physiological transitions associated with sperm capacitation under controlled laboratory conditions. By bringing relevant biochemical and physical cues into the workflow, HyperSperm supports a more biologically informed sperm preparation process for IVF and ICSI.
Seamless Clinical Integration
Standard Selection
Sperm sample is processed and motile sperm are isolated using standard clinic protocols (e.g., density gradient or swim-up).
HyperSperm Processing
Isolated sperm are incubated with HyperSperm media, inducing physiological
capacitation.
Fertilization As Usual
Capacitated sperm are used immediately for ICSI or conventional IVF, requiring no change to the embryologist’s technique.
Clinical Evidence of Impact
Results from controlled IVF studies comparing oocytes from the same cycle show improved embryo development, embryo quality and euploidy outcomes.
EMBRYO DEVELOPMENT (DONOR)
+0%
EMBRYO DEVELOPMENT (PATIENT)
+0%
HIGHER-QUALITY EMBRYOS
+0%
EUPLOID EMBRYOS
+0%
SCIENTIFIC RIGOR
Peer-Reviewed Evidence
A multicenter, prospective sibling oocyte study revealed that HyperSperm™ improves the number and quality of embryos in patients undergoing in vitro fertilization.
First multicenter sibling oocyte study in IVF patients supporting the clinical potential of HyperSperm.
Sperm preparation for intrauterine insemination. Adapting the HyperSperm biological approach for intrauterine insemination.
IN DEVELOPMENT
HyperFlow
Automatization of HyperSperm using microfluidics
IN DEVELOPMENT
Spermy
AI-assisted prediction of outcomes in ART. Exploring data-driven tools to support prediction, insight, and decision-making in assisted reproduction.
LEADERSHIP
Team
Arina Rogozina
CEO
Mariano Buffone
Co-founder | CSO
Dario Krapf
Co-founder | CSO
Matías Gómez Elías
COO
Guillermina Luque
Business Development | Research
Carolina Baró Graf
Business Development | Product
Júlia Marti Clofent
Regulatory | Quality
Núria Correa Mañas
AI | Data Science
Olinda Briski
Sales | Research
Gabriela Carrasquel Martínez
Product | R&D
Ernesto Piga
Product | R&D
María José Martínez Vallejo
Product | R&D
Júlia Garcia Mulet
Lab Technician
Backed by investors who believe in reproductive innovation
Fecundis is supported by investors committed to advancing high-impact science and biotechnology.
Blog
Articles, updates, and perspectives on fertility innovation.
PROYECTO DESARROLLO DE UN DISPOSITIVO AUTOMATIZADO AVANZADO PARA LA SELECCIÓN Y MEJORA FUNCIONAL DE ESPERMATOZOIDES EN TRATAMIENTOS DE FERTILIZACIÓN IN VITRO liderado por FECUNDIS LAB ,S.L (Nº Expediente: EXP – 00175630 / CIIP-20251002)
Fecundis Lab, en colaboración con Beonchip S.L. (España) y la clínica danesa Fertilitets Klinikken Lygten, trabaja en el desarrollo de HyperFlow: un dispositivo totalmente automatizado capaz de seleccionar y mejorar funcionalmente los espermatozoides, con el objetivo de incrementar las tasas de éxito en reproducción asistida humana.
Whether you are a fertility clinic, research partner, investor, or strategic collaborator, we would be glad to hear from you. Get in touch to learn more about our science, our technology, and the next steps in our development.
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking “Accept All”, you consent to our use of cookies.
You can change or withdraw your consent at any time using the privacy settings button.
